Bone marrow transplantation for patients with chronic myeloid leukemia (HLA-identical sibling donors, patients treated February 1981 to December 1984)
Phase observationalN = 70
- Population
- People with CML: 52 in chronic phase and 18 with more advanced disease at transplantation.
- Design
- Treatment series with no comparison group (the abstract does not say whether it was single- or multi-centre): high-dose chemoradiotherapy then allogeneic marrow from HLA-identical siblings; spleen radiotherapy for the 40 patients without prior splenectomy; cyclosporine alone or with T-cell-depleted donor marrow to prevent graft-versus-host disease.
- Arms
- Allogeneic marrow transplant (experimental, n = 70): High-dose chemoradiotherapy followed by marrow from an HLA-identical sibling donor
- People
- Goldman JM, senior author Hows J
Show the numbers
| Endpoint | Analysis | Allogeneic marrow transplant | Control | Effect |
|---|---|---|---|---|
| OSChronic phase at transplantation (52 patients) | primarymedian follow-up 25 monthsGoldman 1986 | 72% at 2 y | — | Actuarial survival as published. 38 of the 52 chronic-phase patients were alive at the median follow-up of 25 months (range 7 to 50). |
| Relapse riskChronic phase at transplantation (52 patients) | primaryGoldman 1986 | 7% | — | Actuarial risk of relapse as published; the abstract does not state the time point. |
| OSMore advanced disease at transplantation (18 patients) | primaryGoldman 1986 | 18% at 2 y | — | Actuarial two-year survival as published; 4 of the 18 patients survived. |
| Relapse riskMore advanced disease at transplantation (18 patients) | primaryGoldman 1986 | 42% | — | Actuarial risk of relapse as published; the abstract does not state the time point. |
| Endpoint | Analysis | Allogeneic marrow transplant | Control | Effect |
|---|---|---|---|---|
| OSChronic phase at transplantation (52 patients) | primarymedian follow-up 25 monthsGoldman 1986 | 72% at 2 y | — | Actuarial survival as published. 38 of the 52 chronic-phase patients were alive at the median follow-up of 25 months (range 7 to 50). |
| Relapse riskChronic phase at transplantation (52 patients) | primaryGoldman 1986 | 7% | — | Actuarial risk of relapse as published; the abstract does not state the time point. |
| OSMore advanced disease at transplantation (18 patients) | primaryGoldman 1986 | 18% at 2 y | — | Actuarial two-year survival as published; 4 of the 18 patients survived. |
| Relapse riskMore advanced disease at transplantation (18 patients) | primaryGoldman 1986 | 42% | — | Actuarial risk of relapse as published; the abstract does not state the time point. |